Application of astragaloside in preparing medication for treating peripheral nervous lesion of diabetes

A technology for peripheral neuropathy and astragaloside IV, which is applied in the field of application of astragaloside IV in the preparation of drugs for treating diabetic peripheral neuropathy, can solve the problems of diabetic peripheral neuropathy that have not been seen with astragaloside IV, and achieve good medicinal prospects , strong effect, lowering blood sugar and glycosylated hemoglobin and promoting insulin secretion

Inactive Publication Date: 2006-04-19
NANJING MEDICAL UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] But so far there has been no relevant report that

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0032] Example 1: The effect of Astragaloside IV (AS-N) on the general physiological conditions of DPN rats

[0033] (1). Materials and methods

[0034] 1 Experimental animals

[0035] Male Sprague-Dawley strain rats, weighing 180-210g, provided by Shanghai Slack Laboratory Animal Co., Ltd., animal certificate number: SCXK (Shanghai) 2003-0003.

[0036] 2 Medicines, reagents and instruments

[0037] Astragaloside IV (AS-IV), with a molecular weight of 784, was extracted from Astragalus by Jiangsu Institute of Medicinal Botany, Chinese Academy of Sciences, and the purity of AS I was confirmed to be greater than 99% by HPLC with the normalization method. Streptozotocin (STZ) was purchased from Calbiochem, Lot. B51229. The blood glucose test kit was purchased from Zhejiang Dongou Biological Engineering Co., Ltd., batch number Lot2004030266. The insulin radioimmunoassay kit was purchased from Beijing China Institute of Atomic Energy, batch number Lot20040701. Epalrestat (EPS) was dona...

Example Embodiment

[0050] Example 2 Effect of Astragaloside IV (AS-IV) on Blood Sugar and Glycated Hemoglobin in DPN Rats

[0051] 1. Materials and methods (same as Example 1)

[0052] 2 results

[0053] Blood glucose and glycosylated hemoglobin (HbA 1 C) It is significantly higher than the normal control group, with a very significant difference (P1 Compared with the DPN group, the blood glucose drop was not obvious in the C; and the high-dose treatment group of AS-IV showed a significant hypoglycemic effect (P1 C was also significantly reduced (P<0.05) (see Table 2).

[0054] Group

[0055] Note: NS group compared with DPN group, ## P<0.01; Compared with the DPN group in the drug treatment group, *P<0.05, **P<0.01

Example Embodiment

[0056] Example 3 The effect of astragaloside IV (AS-IV) on insulin secretion in DPN rats

[0057] The effect of AS-IV on insulin secretion in DPN rats

[0058] The plasma insulin content of rats in the normal group was significantly higher than that of the DPN group (P<0.01), the insulin content of the AS-IV low-dose treatment group only slightly increased, and the plasma insulin content of the high-dose group of AS-IV was significantly higher than that of the DPN group (P<0.01). 0.05), suggesting that AS-IV has the effect of promoting insulin secretion. (See Table 3,).

[0059] Group

[0060] Note: NS group compared with DPN group, ## P<0.01; Compared with the DPN group in the drug treatment group, *P<0.05, **P<0.01

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of astragalus saponin A in preparing the medicines for preventing and treating the diabetic peripheral neuropathy is disclosed. Said medicine applied orally is prepared from the astragalus saponin A and proper additive.

Description

1. Technical field [0001] The present invention relates to the new use of astragaloside IV (ASI), in particular to the application of astragaloside IV in the preparation of medicines for treating diabetic peripheral neuropathy. 2. Background technology [0002] According to statistics, there are currently more than 30 million diabetic patients in my country. WHO predicts that by 2025, the number of diabetic patients in China will reach 50 million. my country has become the second largest diabetic country in the world after India. [1] . The harm of diabetes mainly comes from complications, including neuropathy, retinopathy, vascular disease and diabetic nephropathy. Because the energy of nerve cells mainly depends on glucose, the metabolic disorder caused by high blood sugar can easily induce neuropathy; diabetic neuropathy is one of the earliest and highest incidence complications of diabetic complications, and the lesions involve peripheral nerves and Central nervous syst...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61K9/08A61K9/10A61K9/16A61K9/20A61K9/48A61P3/10A61P25/02
Inventor 张银娣余俊先孙视沈建平张涵庆刘玥辉
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap